Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
life sciences
national blog main
national top stories
novartis
9
×
roche
9
×
san francisco top stories
boston blog main
boston top stories
national
san francisco blog main
cancer
clinical trials
pfizer
indiana blog main
indiana top stories
new york top stories
raleigh-durham blog main
raleigh-durham top stories
boulder/denver blog main
boulder/denver top stories
deals
detroit blog main
detroit top stories
gene therapy
new york blog main
san diego blog main
san diego top stories
seattle blog main
seattle top stories
spark therapeutics
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
amgen
biogen
drug prices
genentech
What
drug
patients
bio
latest
roundup
therapy
blood
cancer
company
crispr
fda
gene
intended
new
plan
therapeutics
access
acquisitions
address
advanced
advantages
albert
alzheimer’s
american
analytics
annual
approval
approved
approves
ash
atrophy
bar
biggest
biofourmis
blueprint
borne
bourla
brings
broader
cancers
Language
unset
unknown
Current search:
roche
×
novartis
×
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More